* Announces results from a category 3 oral human abuse
potential study and a category 3 intranasal hap study of product
candidate ARYMO ER extended-release tablets
The post BRIEF-Egalet announces results after study of ARYMO ER extended-release tablets appeared first on NASDAQ.